Compare JetBlue Airways Corporation (JBLU) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs Neurocrine Biosciences Inc — how do they compare? JetBlue Airways Corporation trades at $5.43 (market cap $2.02B), while Neurocrine Biosciences Inc trades at $173.8 (market cap $17.18B). The key difference: Neurocrine Biosciences Inc is far larger — about 8.5× JetBlue Airways Corporation's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals.
| JBLU | NBIX | |
|---|---|---|
Market Cap | $2.02B | $17.18B |
Sector | Industrials | Health |
52-Week High | $6.46 | $180.55 |
52-Week Low | $4.03 | $123.10 |
Enterprise Value | $9.18B | $16.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $5.42, down 3.9% over 24 hours, reflecting ongoing volatility amid mixed earnings performance and high leverage. The stock shows a neutral technical signal with key support at $5.00, while fundamentals reveal persistent losses with a net income margin of -7.78% in 2025 and elevated debt levels. Recent news highlights strategic expansions, such as the Fort Lauderdale schedule increase and a new payment partnership with ClarityPay, aiming to bolster revenue streams.
Outlook remains cautious due to consecutive earnings misses and negative profitability, though low P/S ratio of 0.22 offers valuation appeal. Risks include fuel cost volatility and competitive pressures, while analyst consensus is neutral with a $5.12 price target. Investment opportunity hinges on successful turnaround execution amid sector headwinds.
Neurocrine Biosciences (NBIX) trades at $173.45, up 1.5% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with 44% revenue growth in Q1 2026, 98.17% gross margins, and consistent earnings beats. Recent pipeline advancements and the Soleno acquisition strengthen its neuroscience portfolio, supporting the positive outlook from 32 buy ratings.
NBIX presents a compelling growth opportunity with upward earnings revisions and a $196.08 consensus price target offering 13% upside. Key risks include pipeline execution and competitive pressures in biopharma. The combination of strong financial performance and positive technical indicators suggests continued momentum potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
